Assessment of the role of vitamin D with or without bone-modulating therapy in non-metastatic breast cancer patients receiving adjuvant non-steroidal aromatase inhibitors
Background: Breast cancer (BC) is classified into luminal A, luminal B, Human epidermal growth factor 2 receptors positive, and triple-negative subtypes, with adjuvant endocrine therapy recommended for hormone receptor-positive disease. This study aimed to evaluate whether vitamin D and bone-modifying therapy improve...